Search Results - "Zhu, Bikang"

Ruboxistaurin maintains the bone mass of subchondral bone for blunting osteoarthritis progression by inhibition of osteoclastogenesis and bone resorption activity by Pang, Cong, Wen, Liangbao, Lu, Xuanyuan, Luo, Shanchao, Qin, Haikuo, Zhang, Xuehui, Zhu, Bikang, Luo, Shixing

“…[Display omitted] •Ruboxistaurin treatment prevents the early progression of osteoarthritis by attenuating ACLT-induced subchondral bone…”
Get full text

Identification of potential specific biomarkers and key signaling pathways between osteogenic and adipogenic differentiation of hBMSCs for osteoporosis therapy by Wu, Jianjun, Cai, Peian, Lu, Zhenhui, Zhang, Zhi, He, Xixi, Zhu, Bikang, Zheng, Li, Zhao, Jinmin

“…Abstract Background The differentiation of bone mesenchymal stem cells (BMSCs) into adipogenesis (AD) rather than osteogenesis (OS) is an important…”
Get full text

Sotrastaurin, a PKC inhibitor, attenuates RANKL‐induced bone resorption and attenuates osteochondral pathologies associated with the development of OA by Pang, Cong, Wen, Liangbao, Qin, Haikuo, Zhu, Bikang, Lu, Xuanyuan, Luo, Shixing

“…Osteoarthritis (OA) is a common degenerative disease that affects the musculoskeletal structure of the whole joint, which is characterized by progressive…”
Get full text

A pH-responsive mesoporous silica nanoparticles-based drug delivery system with controlled release of andrographolide for OA treatment by He, Mingwei, Qin, Zainen, Liang, Xiaonan, He, Xixi, Zhu, Bikang, Lu, Zhenhui, Wei, Qingjun, Zheng, Li

“…Abstract Andrographolide (AG) has favorable anti-inflammatory and antioxidative capacity. However, it has low bioavailability due to high lipophilicity and can…”
Get full text